4//SEC Filing
Fried Robert N 4
Accession 0001628280-25-017223
CIK 0001386570other
Filed
Apr 8, 8:00 PM ET
Accepted
Apr 9, 7:52 PM ET
Size
10.6 KB
Accession
0001628280-25-017223
Insider Transaction Report
Form 4
Fried Robert N
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-04-09$3.30/sh+66,667$220,001→ 1,038,981 total - Exercise/Conversion
Stock Options (right to buy)
2025-04-09−66,667→ 0 totalExercise: $3.30From: 2015-08-30Exp: 2025-07-29→ Common Stock (66,667 underlying)
Holdings
- 250,000(indirect: By Trust)
Common Stock
- 12,746(indirect: See Footnote)
Common Stock
- 250,000(indirect: By Trust)
Common Stock
- 95,001(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on July 29, 2025, paying the exercise price with cash, and has not sold any of the shares received upon exercise.
- [F2]The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F3]6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried.
Documents
Issuer
Niagen Bioscience, Inc.
CIK 0001386570
Entity typeother
Related Parties
1- filerCIK 0001417952
Filing Metadata
- Form type
- 4
- Filed
- Apr 8, 8:00 PM ET
- Accepted
- Apr 9, 7:52 PM ET
- Size
- 10.6 KB